Novo Nordisk (NYSE: NVO) details progress on DKK 15B share repurchase

Rhea-AI Filing Summary

Novo Nordisk A/S provides an update on its ongoing share repurchase programme conducted under EU Safe Harbour Rules. The company is running a 12‑month buyback of up to DKK 15 billion that began on 4 February 2026, including a sub‑programme started on 6 May 2026 to repurchase B shares for up to DKK 11,200,000,010.45.

As of 3 July 2026, Novo Nordisk has repurchased a total of 23,009,179 B shares at an average price of DKK 270.32 per share, for a transaction value of DKK 6,219,775,971. Following recent purchases, the company holds 40,194,480 B shares as treasury shares, equal to 0.9% of its share capital, out of a total of 4,465,000,000 A and B shares outstanding including treasury shares.

Key Figures

Overall buyback capacity: DKK 15 billion Sub-programme limit: DKK 11,200,000,010.45 Shares repurchased to date: 23,009,179 B shares +5 more

8 metrics

Overall buyback capacity DKK 15 billion 12-month share repurchase beginning 4 February 2026

Sub-programme limit DKK 11,200,000,010.45 B share repurchases from 6 May 2026 to 1 February 2027

Shares repurchased to date 23,009,179 B shares Total repurchased since 4 February 2026 as of 3 July 2026

Average repurchase price DKK 270.32 per B share Average price on 23,009,179 B shares as of 3 July 2026

Total buyback value to date DKK 6,219,775,971 Transaction value for 23,009,179 B shares as of 3 July 2026

Treasury B shares held 40,194,480 B shares Treasury position after recent transactions, equal to 0.9% of share capital

Total A and B shares 4,465,000,000 shares Total share count including treasury shares

Recent daily repurchase example 200,000 B shares at DKK 326.71 Purchase on 3 July 2026, transaction value DKK 65,342,713

Key Terms

share repurchase programme, Safe Harbour Rules, treasury shares, foreign private issuer, +1 more

5 terms

share repurchase programme financial

"Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014"

A share repurchase programme is a company's plan to buy back its own shares from the market. This reduces the total number of shares available, which can increase the value of remaining shares and signal confidence in the company's health. For investors, it can indicate that the company believes its stock is undervalued and may lead to higher share prices.

Safe Harbour Rules regulatory

"the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules")"

treasury shares financial

"Novo Nordisk owns a total of 40,194,480 B shares of DKK 0.10 as treasury shares"

Treasury shares are a company’s own stock that it has repurchased and keeps on its books instead of canceling or leaving in the hands of outside investors. Think of them like coupons a business puts back in a drawer: they don’t vote or receive dividends while held, but they can be reissued later for employee pay or fundraising. For investors this matters because buybacks change the number of shares that count toward earnings and ownership, can boost per‑share metrics, and use corporate cash that might otherwise go to growth or dividends.

foreign private issuer regulatory

"REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

B shares financial

"Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 07/06/2026 - 07:00 AM Accepted by SEC EDGAR 07/06/2026 - 07:00 AM Learn about SEC filing dates

FAQ

What is the size of Novo Nordisk (NVO) current share repurchase programme?

Novo Nordisk plans to repurchase up to DKK 15 billion of B shares over a 12‑month period beginning 4 February 2026. This includes a sub‑programme started on 6 May 2026 with a ceiling of DKK 11,200,000,010.45.

How many Novo Nordisk (NVO) shares have been repurchased so far in 2026?

As of 3 July 2026, Novo Nordisk has repurchased 23,009,179 B shares since 4 February 2026. These shares were bought at an average price of DKK 270.32 per B share, for a total value of DKK 6,219,775,971.

What portion of Novo Nordisk (NVO) share capital is held in treasury?

Novo Nordisk now holds 40,194,480 B shares of nominal DKK 0.10 as treasury shares. This represents 0.9% of the company’s total share capital, based on overall A and B shares outstanding including treasury holdings.

How many total shares does Novo Nordisk (NVO) have outstanding?

The total number of A and B shares in Novo Nordisk is 4,465,000,000, including treasury shares. This figure provides context for the current buyback scale relative to the company’s overall equity base.

Over what period is Novo Nordisk (NVO) running its DKK 15 billion buyback?

The DKK 15 billion share repurchase programme runs over a 12‑month period beginning on 4 February 2026. Within this timeframe, a specific sub‑programme for B shares operates from 6 May 2026 to 1 February 2027.

Under which rules is Novo Nordisk (NVO) conducting its share repurchase programme?

Novo Nordisk is conducting the share repurchase under Article 5 of Regulation No 596/2014 (MAR) and Commission Delegated Regulation (EU) 2016/1052. These are the EU “Safe Harbour Rules” that set conditions for market buyback programmes.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________

FORM 6-K

________________

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934

July 6, 2026

________________

NOVO NORDISK A/S

 (Exact name of Registrant as specified in its charter)

Novo Allé 1

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒           Form 40-F ☐

 

 

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 6 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027.

Since the announcement 29 June 2026, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	7,250,000		2,098,848,921
29 June 2026	200,000	314.24	62,847,300
30 June 2026	200,000	318.15	63,630,624
1 July 2026	200,000	320.42	64,083,705
2 July 2026	200,000	325.11	65,022,718
3 July 2026	200,000	326.71	65,342,713
Accumulated under the programme	8,250,000		2,419,775,981

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 40,194,480 B shares of DKK 0.10 as treasury shares, corresponding to 0.9% of the share capital. The total amount of A and B shares in the company is 4,465,000,000 including treasury shares.

Page 2 of 2

Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 4 February 2026. As of 3 July 2026, Novo Nordisk has since 4 February 2026 repurchased a total 23,009,179 B shares at an average share price of DKK 270.32 per B share equal to a transaction value of DKK 6,219,775,971.

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 67,900 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown		Liz Skrbkova (US)
+45 3079 9289		+1 609 917 0632
globalmedia@novonordisk.com		lzsk@novonordisk.com
Investors:
Michael Novod		Jacob Martin Wiborg Rode
+45 3075 6050		+45 3075 5956
nvno@novonordisk.com		jrde@novonordisk.com
Ida Schaap Melvold		Sina Meyer
+45 3077 5649		+45 3079 6656
idmg@novonordisk.com		azey@novonordisk.com
Alex Bruce		Christoffer Sho Togo Tullin
+45 3444 2613		+45 3079 1471
axeu@novonordisk.com		cftu@novonordisk.com
Frederik Taylor Pitter		Mads Berner Bruun
+1 609 613 0568		+45 3075 2936
fptr@novonordisk.com		mbbz@novonordisk.com

Novo Nordisk A/S Investor Relations	Novo Allé 1 2880 Bagsværd Denmark	Telephone: +45 4444 8888	www.novonordisk.com CVR no: 24 25 67 90
			Company announcement No 41/ 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: July 6, 2026   NOVO NORDISK A/S   Maziar Mike Doustdar Chief Executive Officer